Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists

@inproceedings{Giorgino2016TreatmentII,
  title={Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists},
  author={Francesco Giorgino and Riccardo C Bonadonna and Sandro Gentile and Roberto Vettor and Paolo Pozzilli},
  booktitle={Diabetes/metabolism research and reviews},
  year={2016}
}
A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti-diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1… CONTINUE READING